Biocon Biologics to Supply its Oncology Biosimilars to NCSM

Bengaluru, June 24, 2025 – Biocon Limited (NSE: BIOCON, BSE: 532523), through its biosimilars arm Biocon Biologics Ltd. (BBL), has entered into a strategic collaboration with the National Cancer Society of Malaysia (NCSM) to roll out a Patient Assistance Program (PAP).

The initiative, signed during the National Cancer Congress Malaysia 2025, aims to expand access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. It expands Biocon’s outreach in Malaysia, helping it build on its previous success in expanding access to diabetes care there.

As of 12:42 PM, Biocon’s share is trading at ₹349.25 (down 1.05% from its previous close).

Biocon Biologics-NCSM Partnership: Key Highlights

The MoU was formalized on the sidelines of the National Cancer Congress Malaysia 2025, in the presence of Datuk Seri Dr Dzulkefly Ahmad, Malaysia’s Minister of Health.

Under this initiative:

• Biocon Biologics will supply biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab
• NCSM will manage patient enrolment and medicine distribution
• The PAP will initially focus on bTrastuzumab for patients whose treatment is delayed due to financial constraints

“Our partnership with NCSM marks a meaningful step in expanding access to high-quality oncology biosimilars,” said Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics.

“This collaboration aims to ease the treatment burden for underserved populations and help improve inclusive, patient-centric healthcare outcomes in Malaysia.”

Strategic Impact and ESG Focus

Biocon Biologics, which has previously reached 345,000+ patients in Malaysia through its diabetes care efforts, is now intensifying its focus on oncology through targeted partnerships.

This new PAP is aligned with the company’s ESG vision to advance health equity and support UN Sustainable Development Goals, especially those related to affordable healthcare access and community well-being.

Market Outlook

Despite the landmark ESG bond listing, L&T’s share saw only limited upside as investors weighed long-term sustainability goals against short-term earnings impact. The move signals strategic strength, but market caution likely capped gains amid broader macroeconomic uncertainties and muted immediate financial effect.

Company Background

Biocon Biologics operates in 120+ countries, including the U.S., EU, Japan, and Australia. The company leverages cutting-edge science, global manufacturing scale, and cost-efficient innovation to deliver affordable biologics across therapy areas such as oncology, immunology, diabetology, and ophthalmology.

Regulatory Note:

This announcement has been filed with BSE and NSE as per applicable SEBI guidelines and is available on the company’s website.

REF: https://nsearchives.nseindia.com/corporate/Biocon2_24062025085406_SEPressrelase-24062025.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations